[ U.S. CDMRP - ALS Therapeutic Idea Award | Research Funding ]
Event details
| Date | 27.03.2020 |
| Category | Call for proposal |
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the Amyotrophic Lateral Sclerosis (ALS) Research Program Therapeutic Idea Award. This Award supports hypothesis-driven therapeutic development and is designed to promote new ideas aimed at drug or treatment discovery that are still in the early stages of development. Development and/or modification of preclinical model systems or the application of high-throughput screens to define or assess lead compounds for ALS treatment may also be proposed. All research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Preliminary data are not required. Projects that focus primarily on investigating the pathophysiology of ALS, without consideration of therapeutic development, are not within the scope of this Funding Opportunity.
The FY20 ALSRP Therapeutic Idea Award Therapeutically Relevant Biomarker Option encourages applicants to include the development of biomarker(s) in parallel with the main proposed Therapeutic Idea Award research effort. Additional funding is being offered for the co-development of biomarkers that will enhance the drug development process.
Funding: max. $500’000
max. $600’000 (with biomarker option)
Duration: 2 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Applicants must be independent investigators, but can come from any academic level.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a list of collaborators and key personnel, a preproposal narrative, and supporting documentation as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 27 March 2020, 5:00 p.m.
Full Application Deadline: 23 July 2020, 11:59 p.m. EST
Grants.gov Funding Opportunity Number: W81XWH-20-ALSRP-TIA
Further information
The FY20 ALSRP Therapeutic Idea Award Therapeutically Relevant Biomarker Option encourages applicants to include the development of biomarker(s) in parallel with the main proposed Therapeutic Idea Award research effort. Additional funding is being offered for the co-development of biomarkers that will enhance the drug development process.
Funding: max. $500’000
max. $600’000 (with biomarker option)
Duration: 2 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Applicants must be independent investigators, but can come from any academic level.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a list of collaborators and key personnel, a preproposal narrative, and supporting documentation as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 27 March 2020, 5:00 p.m.
Full Application Deadline: 23 July 2020, 11:59 p.m. EST
Grants.gov Funding Opportunity Number: W81XWH-20-ALSRP-TIA
Further information
- To see the program announcement, navigate to the search page on Grants.gov and search for the Opportunity Number W81XWH-20-ALSRP-TIA
- For questions about the eBRAP or Grants.gov platforms, contact the Research Office.
Practical information
- General public
- Free